| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0014-2999(90)90204-J |
| P698 | PubMed publication ID | 2171955 |
| P50 | author | Ramon Trullas | Q43157030 |
| P2093 | author name string | P Skolnick | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-10 | |
| P577 | publication date | 1990-08-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Functional antagonists at the NMDA receptor complex exhibit antidepressant actions | |
| P478 | volume | 185 |
| Q30418172 | 1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. |
| Q37310521 | A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders |
| Q47640228 | A brief history of antidepressant drug development: from tricyclics to beyond ketamine |
| Q38771892 | A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice |
| Q48262461 | A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment |
| Q37179033 | A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders |
| Q24630153 | A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression |
| Q44334290 | A rapid method for evaluating the behavioral effects of phencyclidine-like dissociative anesthetics in mice |
| Q38227967 | A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes |
| Q48656226 | ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats |
| Q44239962 | Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine. |
| Q39093325 | Administration of ketamine for unipolar and bipolar depression. |
| Q30457479 | Advances in the treatment of anxiety: targeting glutamate |
| Q39371468 | Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb |
| Q38591030 | Antidepressant Effects of Mallotus oppositifolius in Acute Murine Models |
| Q78440735 | Antidepressant activity and calcium signaling cascades |
| Q44019712 | Antidepressant activity of S-adenosyl-L-methionine in mice and rats |
| Q68029025 | Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats |
| Q29617327 | Antidepressant effects of ketamine in depressed patients |
| Q26800231 | Antidepressant mechanism of ketamine: perspective from preclinical studies |
| Q34622363 | Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission |
| Q37642659 | Antidepressant properties of aqueous macerate from Gladiolus dalenii corms |
| Q47148667 | Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models |
| Q53972514 | Antidepressant-like actions of an AMPA receptor potentiator (LY392098). |
| Q44462663 | Antidepressant-like effect of agmatine and its possible mechanism |
| Q42614907 | Antidepressant-like effect of lead in adult mice |
| Q46773296 | Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test |
| Q71943023 | Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression |
| Q53976705 | Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. |
| Q42602477 | Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats |
| Q46516278 | Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests |
| Q43685912 | Antidepressant-like properties of zinc in rodent forced swim test |
| Q33709227 | Antidepressants for the new millennium |
| Q34061082 | Antidepressants: past, present and future |
| Q48077200 | Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. |
| Q49141013 | Behavioral effects in the elevated plus maze of an NMDA antagonist injected into the dorsal hippocampus: influence of restraint stress |
| Q33231128 | Beyond monoamines: glutamatergic function in mood disorders |
| Q34123893 | Cellular mechanisms in the vulnerability to depression and response to antidepressants |
| Q46829332 | Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function? |
| Q73963095 | Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test |
| Q48377216 | Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study |
| Q48226196 | Chronic but not acute clomipramine alters the effect of NMDA receptor regulation of dopamine release in rat frontal cortex |
| Q48253531 | Chronic clomipramine administration reverses NMDA-evoked decreases in dopamine release in the raphe nuclei |
| Q45235868 | Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex |
| Q51075863 | Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. |
| Q45201609 | Chronic treatment with milnacipran reverses the impairment of synaptic plasticity induced by conditioned fear stress |
| Q42359901 | Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents. |
| Q52667723 | Convergent Mechanisms Underlying Rapid Antidepressant Action. |
| Q42785072 | Cracking the moody brain: lifting the mood with ketamine |
| Q28244223 | Current investigational drugs for major depression |
| Q37202885 | Current status of ketamine and related compounds for depression |
| Q52213672 | D-Cycloserine: Agonist turned antagonist. |
| Q59052088 | D-Serine in Neuropsychiatric Disorders: New Advances |
| Q36785486 | D-serine as a gliotransmitter and its roles in brain development and disease |
| Q61806582 | Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines |
| Q36085611 | Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray |
| Q48653526 | Depression: comfortably numb |
| Q61959801 | Depressive Disorders: Prevalence, Costs, and Theories |
| Q48298710 | Dietary magnesium restriction reduces amygdala-hypothalamic GluN1 receptor complex levels in mice |
| Q34413503 | Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model |
| Q48509722 | Differential effects of predator stress and the antidepressant tianeptine on physiological plasticity in the hippocampus and basolateral amygdala |
| Q63431058 | Dizocilpine prevents the enhanced locomotor response to quinpirole induced by repeated electroconvulsive shock |
| Q48601578 | Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists |
| Q34701029 | Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? |
| Q48732759 | Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial |
| Q41851146 | Effect of 1-aminocyclopropanecarboxylic acid on N-methyl-D-aspartate-stimulated [3H]-noradrenaline release in rat hippocampal synaptosomes |
| Q43270515 | Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats |
| Q47889297 | Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. |
| Q43244719 | Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats |
| Q34653628 | Effects of Chronic D-Serine Elevation on Animal Models of Depression and Anxiety-Related Behavior |
| Q38349251 | Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies. |
| Q41861044 | Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats |
| Q43092657 | Effects of depressive-like behavior of rats on brain glutamate uptake. |
| Q43596296 | Effects of olfactory bulbectomy on NMDA receptor density in the rat brain:. |
| Q92142456 | Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature |
| Q37984619 | Emerging drugs for major depressive disorder |
| Q35770190 | Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology |
| Q35111592 | Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression |
| Q35236446 | Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders. |
| Q37242260 | Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2) |
| Q59138279 | Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors |
| Q89747382 | Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1 |
| Q53426928 | Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. |
| Q38574831 | Five potential therapeutic agents as antidepressants: a brief review and future directions |
| Q43936630 | Forced swimming evokes a biphasic response in CREB phosphorylation in extrahypothalamic limbic and neocortical brain structures in the rat. |
| Q30508512 | Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression |
| Q41261517 | Functional changes in neuronal systems induced by phencyclidine administration |
| Q36066308 | GABA and glutamate systems as therapeutic targets in depression and mood disorders |
| Q36668325 | GABAergic control of depression-related brain states |
| Q42680585 | Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice |
| Q26798929 | Glia in the cytokine-mediated onset of depression: fine tuning the immune response |
| Q27015761 | Glial degeneration as a model of depression |
| Q34729421 | GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine |
| Q38838637 | Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine |
| Q34982546 | Glutamate and its role in psychiatric illness |
| Q33874459 | Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. |
| Q38895017 | Glutamate-Based Drug Discovery for Novel Antidepressants |
| Q35148291 | Glutamatergic drive of the dorsal raphe nucleus |
| Q34398007 | Glutamatergic modulators: the future of treating mood disorders? |
| Q57471889 | Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies |
| Q33693745 | Group I metabotropic glutamate receptors: implications for brain diseases |
| Q34098184 | Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? |
| Q73272050 | Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat |
| Q34435949 | Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties |
| Q73088643 | Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex--a possible mechanism of neuroprotection in major depression? |
| Q46956150 | Immunological aspects of depressive disorders |
| Q33896467 | Increased cerebrospinal fluid glutamine levels in depressed patients |
| Q28288750 | Inflammatory biomarkers and depression |
| Q38088733 | Innovations in CNS drug discovery: differentiating strategies to treat depression |
| Q48717342 | Intra- and interstrain differences in models of "behavioral despair". |
| Q37957965 | Investigational NMDA receptor modulators for depression |
| Q28241221 | Invited review: the evolution of antidepressant mechanisms |
| Q30478314 | Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour |
| Q46726967 | Involvement of sigma (sigma1) receptors in modulating the anti-depressant effect of neurosteroids (dehydroepiandrosterone or pregnenolone) in mouse tail-suspension test |
| Q34551188 | Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression |
| Q34475595 | Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review |
| Q34480719 | Ketamine and phencyclidine: the good, the bad and the unexpected |
| Q34978041 | Ketamine and the next generation of antidepressants with a rapid onset of action |
| Q36905864 | Ketamine as a novel antidepressant: from synapse to behavior |
| Q35547495 | Ketamine as a promising prototype for a new generation of rapid-acting antidepressants |
| Q90631290 | Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives |
| Q92898149 | Ketamine: A Review for Clinicians |
| Q89548916 | Ketamine: Leading us into the future for development of antidepressants |
| Q89527723 | Ketamine: The final frontier or another depressing end? |
| Q37330681 | Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties |
| Q58213893 | Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies |
| Q46328639 | Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test |
| Q53441048 | Lack of metabolism in (R)-ketamine's antidepressant actions in a chronic social defeat stress model. |
| Q46610466 | Lack of persistent effects of ketamine in rodent models of depression |
| Q34167966 | Magnesium and affective disorders |
| Q52658612 | Mechanisms of ketamine action as an antidepressant. |
| Q33814386 | Mechanisms underlying the antidepressant response and treatment resistance. |
| Q41926184 | Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function |
| Q41876109 | Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists |
| Q80188585 | Modulation of antidepressant-like activity of magnesium by serotonergic system |
| Q28361105 | Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands |
| Q36871849 | Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems |
| Q91173369 | Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites |
| Q48825592 | Motor activity and quantitative autoradiographic analysis of muscarinic receptors in the brain of rats subjected to the forced swimming test |
| Q37277388 | NMDA Receptor Antagonists for Treatment of Depression |
| Q38211107 | NMDA antagonists under investigation for the treatment of major depressive disorder |
| Q34974649 | NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test |
| Q41986238 | NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum |
| Q48689485 | NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice |
| Q44000229 | NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress, GABA levels and NMDA receptor binding in rat hippocampus |
| Q45927226 | NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. |
| Q37323300 | NMDA receptors and the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice |
| Q36901682 | Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. |
| Q39311440 | Neurobiological mechanisms of stress resilience and implications for the aged population. |
| Q36532151 | Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders |
| Q34083488 | Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant |
| Q46325049 | Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression |
| Q37709574 | New approaches to the pharmacological management of major depressive disorder |
| Q34507177 | New targets for rapid antidepressant action |
| Q28743068 | New therapeutic targets for mood disorders |
| Q77965235 | Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test |
| Q48170449 | Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 2. Chronic treatment results in downregulation of cortical beta-adrenoceptors |
| Q55263216 | Nitrous Oxide Induces Prominent Cell Proliferation in Adult Rat Hippocampal Dentate Gyrus. |
| Q36498659 | Novel Glutamatergic Treatments for Severe Mood Disorders |
| Q95643364 | Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators |
| Q35661119 | Novel glutamatergic agents for major depressive disorder and bipolar disorder |
| Q38131480 | Novel glutamatergic drugs for the treatment of mood disorders |
| Q37064021 | Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings |
| Q89728609 | Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant |
| Q37831342 | Pathobiological targets of depression. |
| Q55353842 | Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study. |
| Q28377976 | Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models |
| Q34353745 | Potential antidepressive properties of amantadine, memantine and bifemelane |
| Q39015847 | Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors |
| Q37718994 | Pregnanolone Glutamate, a Novel Use-Dependent NMDA Receptor Inhibitor, Exerts Antidepressant-Like Properties in Animal Models |
| Q92485132 | Prelimbic neuronal nitric oxide synthase inhibition exerts antidepressant-like effects independently of BDNF signalling cascades |
| Q48120412 | Presynaptic α4β2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. |
| Q43867300 | Prolonged effect of an anesthetic dose of ketamine on behavioral despair |
| Q34766451 | Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments |
| Q33922884 | Psychiatric disorders: diagnosis to therapy |
| Q35709414 | Quantitative analysis of glutamatergic innervation of the mouse dorsal raphe nucleus using array tomography. |
| Q27310950 | Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors |
| Q38838307 | Rapid Resolution of Grief with IV Infusion of Ketamine: A Unique Phenomenological Experience |
| Q24614410 | Rapid antidepressant effects: moving right along |
| Q36899381 | Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond |
| Q44666870 | Reduced isolation-induced aggressiveness in mice following NAALADase inhibition. |
| Q35054086 | Reduced levels of NR1 and NR2A with depression-like behavior in different brain regions in prenatally stressed juvenile offspring |
| Q44111470 | Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats |
| Q44535421 | Repeated administration of antidepressants decreases field potentials in rat frontal cortex |
| Q42509189 | Repeated but not acute clomipramine decreases the effect of N-methyl-D-aspartate receptor activation on serotonergic transmission between the raphe nuclei and frontal cortex |
| Q47389140 | Repeated treatment with nitric oxide synthase inhibitor attenuates learned helplessness development in rats and increases hippocampal BDNF expression |
| Q51097657 | Role of NMDA receptors in the emotional memory associated with neuroendocrine responses to conditioned fear stimuli in the rat. |
| Q42876751 | Role of ventral hippocampal NMDA receptors in anxiolytic-like effect of morphine |
| Q46263887 | Selective breeding for helplessness in rats alters the metabolic profile of the hippocampus and frontal cortex: a 1H-MRS study at 9.4 T. |
| Q28344624 | Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors |
| Q54139906 | Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. |
| Q38061522 | Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin |
| Q47775588 | Slc7a11 (xCT) protein expression is not altered in the depressed brain and system xc- deficiency does not affect depression-associated behaviour in the corticosterone mouse model |
| Q42516758 | Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity |
| Q44773106 | Stress, depression and the hippocampus |
| Q44284822 | Stress- and antidepressant treatment-induced modifications of 5-HT₇ receptor functions in the rat brain |
| Q28729135 | Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment |
| Q51057089 | Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex. |
| Q44071645 | Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats |
| Q38743867 | Targeting glutamate signalling in depression: progress and prospects |
| Q37143117 | Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders |
| Q27004490 | Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date |
| Q33989695 | The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review |
| Q30373328 | The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. |
| Q39758341 | The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits |
| Q46047672 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression |
| Q91712775 | The critical importance of basic animal research for neuropsychiatric disorders |
| Q35822283 | The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats |
| Q41897251 | The effects of BTS 54,505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo |
| Q36800963 | The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression |
| Q55922778 | The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities |
| Q56453443 | The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? |
| Q47995800 | The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes |
| Q34061085 | The role of dopamine in the mechanism of action of antidepressant drugs |
| Q37067679 | The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects |
| Q73052683 | The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist |
| Q37668014 | Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder |
| Q38246286 | Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine |
| Q48641373 | Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. |
| Q36579258 | Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice |
| Q51434894 | Tolerance to anxiolytic- and antidepressant-like effects of a partial agonist of glycineB receptors. |
| Q34924483 | Toluene has antidepressant-like actions in two animal models used for the screening of antidepressant drugs. |
| Q24632936 | Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders |
| Q35739457 | Translating glutamate: from pathophysiology to treatment |
| Q42015236 | Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. |
| Q26773084 | Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy |
| Q37891098 | Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited |
| Q33702477 | Two populations of glutamatergic axons in the rat dorsal raphe nucleus defined by the vesicular glutamate transporters 1 and 2 |
| Q47112810 | UV irradiation to mouse skin decreases hippocampal neurogenesis and synaptic protein expression via HPA axis activation |
| Q34442321 | Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release |
| Q47797859 | What is hydroxynorketamine and what can it bring to neurotherapeutics? |
| Q48436906 | Zinc deficiency alters responsiveness to antidepressant drugs in mice |
| Q26786214 | Zinc in the Glutamatergic Theory of Depression |
Search more.